Saturday - September 13, 2025
Phase 2a DAISY proof-of-concept combination study update
August 28, 2025
NEW BRUNSWICK, New Jersey, Aug. 28 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:

* * *

Phase 2a DAISY proof-of-concept combination study update

*

The Phase 2a DAISY proof-of-concept study evaluating the combination of nipocalimab with an anti-tumor necrosis factor alpha (anti-TNFa) therapy in rheumatoid arthritis (RA) patients with refractory disease was an innovative approach to test if the combin . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products